MCID: VTL004
MIFTS: 62

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Categories: Genetic diseases, Rare diseases, Skin diseases, Immune diseases

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 53 28 13 37 69
Vitiligo 53 37 12 72 49 24 36 28 51 40 41 14 69
Vamas1 53 71
Slev1 53 71
Vtlg 53 24
Systemic Lupus Erythematosus, Vitiligo-Related; Slev1 53
Vitiligo-Associated Multiple Autoimmune Disease 1 71
Systemic Lupus Erythematosus, Vitiligo-Related 53
Systemic Lupus Erythematosus Vitiligo-Related 71
Vitiligo; Vtlg 53

Characteristics:

HPO:

31
vitiligo-associated multiple autoimmune disease susceptibility 1:
Inheritance polygenic inheritance


Classifications:



External Ids:

OMIM 53 606579
Disease Ontology 12 DOID:12306
ICD10 32 L80
ICD9CM 34 709.01
NCIt 46 C26915
SNOMED-CT 64 156437000 56727007
MedGen 39 C1847835
KEGG 36 H01372

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

NIH Rare Diseases : 49 Vitiligo is a pigmentation disorder in which melanocytes (the cells that make pigment) in the skin are destroyed. As a result, white patches appear on the skin in different parts of the body, and sometimes also on both the mucous membranes and the retina. The average age of onset is in the mid-20s. It is generally considered to be an autoimmune disorder, and about 20-25 percent of people with vitiligo also have at least one other autoimmune disorder. In the absence of other conditions, vitiligo does not affect general health; however, concerns about appearance and ethnic identity are significant issues for many affected individuals. The exact cause of vitiligo is not known, but there are several different theories. There is strong evidence that people with vitiligo inherit a group of genes that make them susceptible to depigmentation. The main goal of treating vitiligo is to improve appearance; current treatment options include medication, surgery, and adjunctive therapies (used along with surgical or medical treatments). Last updated: 11/20/2012

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1, also known as vitiligo, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and lupus erythematosus, and has symptoms including vitiligo, pruritus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 is NLRP1 (NLR Family Pyrin Domain Containing 1), and among its related pathways/superpathways are NOD-like receptor signaling pathway and NF-kappaB Signaling. The drugs Pimecrolimus and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and thyroid, and related phenotypes are homeostasis/metabolism and hematopoietic system

OMIM : 53 Generalized vitiligo is an autoimmune disease characterized by melanocyte loss, which results in patchy depigmentation of skin and hair, and is associated with an elevated risk of other autoimmune diseases. It is a genetically complex disorder involving multiple susceptibility genes and unknown environmental triggers. Patients with generalized vitiligo have elevated frequencies of other autoimmune diseases, suggesting that these diseases involve shared genetic components (summary by Jin et al., 2010). (606579)

UniProtKB/Swiss-Prot : 71 Vitiligo-associated multiple autoimmune disease 1: A disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.

MedlinePlus : 40 Vitiligo causes white patches on your skin. It can also affect your eyes, mouth, and nose. It occurs when the cells that give your skin its color are destroyed. No one knows what destroys them. It is more common in people with autoimmune diseases, and it might run in families. It usually starts before age 40. The white patches are more common where your skin is exposed to the sun. In some cases, the patches spread. Vitiligo can cause your hair to gray early. If you have dark skin, you may lose color inside your mouth. Using sunscreen will help protect your skin, and cosmetics can cover up the patches. Treatments for vitiligo include medicines, light therapy, and surgery. Not every treatment is right for everyone. Many have side effects. Some take a long time. Some do not always work. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Genetics Home Reference : 24 Vitiligo is a condition that causes patchy loss of skin coloring (pigmentation). The average age of onset of vitiligo is in the mid-twenties, but it can appear at any age. It tends to progress over time, with larger areas of the skin losing pigment. Some people with vitiligo also have patches of pigment loss affecting the hair on their scalp or body.

Disease Ontology : 12 A hypersensitivity reaction type II disease that causes depigmentation of patches of skin resulting from loss of function or death of melanoctyes.

Wikipedia : 72 Vitiligo is a long-term skin condition characterized by patches of the skin losing their pigment. The... more...

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 29.8 AIRE CTLA4 PTPN22 TPO
2 lupus erythematosus 29.6 C4B CTLA4 NLRP1 PTPN22
3 vitiligo-associated multiple autoimmune disease susceptibility 6 11.4
4 tyrosinase-like 10.5 TYR TYRP1
5 skin/hair/eye pigmentation, variation in, 3 10.5 MITF TYR
6 halo nevi 10.5 PMEL TYR
7 gallbladder melanoma 10.5 MITF PMEL
8 albinism, ocular, with sensorineural deafness 10.5 MITF TYR
9 melanotic neurilemmoma 10.5 PMEL TYR
10 diffuse meningeal melanocytosis 10.5 PMEL TYR
11 melanoacanthoma 10.5 PMEL TYR
12 pigmented basal cell carcinoma 10.5 MITF TYR
13 epithelioid cell melanoma 10.4 MITF TYR
14 breast angiosarcoma 10.4 MITF TYR
15 type 1 diabetes mellitus 17 10.4 AIRE CTLA4
16 tietz albinism-deafness syndrome 10.4 MITF TYR
17 malignant spindle cell melanoma 10.4 MITF PMEL TYR
18 waardenburg syndrome, type 2e 10.4 KITLG MITF
19 dyschromatosis symmetrica hereditaria 10.4 MITF TYR TYRP1
20 albinism 10.4 MITF TYR TYRP1
21 amelanotic melanoma 10.4 CAT TYR TYRP1
22 congenital rubella 10.3 CAT TPO
23 melanoma, uveal 10.3 MITF PMEL TYR
24 anterior uveitis 10.3 CTLA4 PTPN22
25 hermansky-pudlak syndrome 3 10.2 MITF PMEL TYR TYRP1
26 alopecia areata 10.2 AIRE CTLA4 PTPN22
27 microphthalmia 10.2 MITF PMEL TYR TYRP1
28 lentigines 10.1 MITF POMC TYR
29 autoimmune addison disease 10.1 AIRE CTLA4 NLRP1 PTPN22
30 adrenal cortical hypofunction 10.1 AIRE POMC PTPN22
31 cell type cancer 10.1 CTLA4 MITF PMEL TYR
32 pediatric systemic lupus erythematosus 10.1 C4B PTPN22
33 hypersensitivity reaction disease 10.1 AIRE CTLA4 TPO
34 waardenburg's syndrome 10.1 KITLG MITF TYR TYRP1
35 vogt-koyanagi-harada disease 10.1 NLRP1 PMEL PTPN22 TYR TYRP1
36 celiac disease 1 10.0 CTLA4 PTPN22 TPO
37 autoimmune disease of endocrine system 10.0 AIRE CTLA4 PTPN22 TPO
38 hypothyroidism, congenital, nongoitrous, 4 10.0 POMC TPO
39 hyperphenylalaninemia 10.0 CAT GCH1 PCBD1
40 cutaneous solitary mastocytoma 10.0 KITLG POMC
41 hashimoto thyroiditis 10.0 AIRE CTLA4 PTPN22 TPO
42 myxedema 10.0 CTLA4 TPO
43 oculogyric crisis 9.9 DDC GCH1
44 systemic lupus erythematosus 9.9
45 autoimmune disease 2 9.9
46 autoimmune disease 3 9.9
47 graves' disease 9.8 CTLA4 PTPN22 TPO
48 autoimmune disease 9.8 AIRE CTLA4 NLRP1 PTPN22 TPO
49 skin melanoma 9.8 FGF2 MITF PMEL TYR
50 dowling-degos disease 1 9.7 KITLG MITF POMC TYR TYRP1

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:



Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Clinical features from OMIM:

606579

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

31
# Description HPO Frequency HPO Source Accession
1 vitiligo 31 HP:0001045

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:


pruritus, exanthema

MGI Mouse Phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 DDC AIRE FGF2 C4B GCH1 CAT
2 hematopoietic system MP:0005397 10.26 AIRE FGF2 C4B CTLA4 KITLG PMEL
3 cardiovascular system MP:0005385 10.22 DDC FGF2 C4B GCH1 CTLA4 KITLG
4 mortality/aging MP:0010768 10.21 DDC AIRE FGF2 C4B GCH1 CAT
5 immune system MP:0005387 10.17 DDC AIRE C4B CTLA4 KITLG POMC
6 endocrine/exocrine gland MP:0005379 10.11 AIRE CTLA4 KITLG POMC PTPN22 MITF
7 integument MP:0010771 10.01 KITLG CTLA4 PMEL POMC MITF PCBD1
8 hearing/vestibular/ear MP:0005377 9.97 FGF2 KITLG MITF TPO TYR TYRP1
9 nervous system MP:0003631 9.96 KITLG DDC AIRE FGF2 GCH1 MCHR1
10 neoplasm MP:0002006 9.87 AIRE FGF2 CAT KITLG POMC TYR
11 pigmentation MP:0001186 9.76 KITLG CTLA4 TYR POMC MITF PCBD1
12 skeleton MP:0005390 9.56 KITLG FGF2 CTLA4 MCHR1 MITF TPO
13 vision/eye MP:0005391 9.32 DDC AIRE FGF2 KITLG PMEL TYR

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pimecrolimus Approved, Investigational Phase 4,Phase 2 137071-32-0 17753757 6447131
2
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
3
Acetylcholine Approved Phase 4 51-84-3 187
4
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
5
Hydroquinone Approved, Investigational Phase 4 123-31-9 785
6
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
7 Analgesics Phase 4,Phase 2
8 Analgesics, Non-Narcotic Phase 4,Phase 2
9 Anti-Allergic Agents Phase 4
10 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
12 Antirheumatic Agents Phase 4,Phase 2,Phase 1
13 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
14 Dermatologic Agents Phase 4,Phase 2,Phase 1
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
16 mometasone furoate Phase 4
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
18 Anti-Asthmatic Agents Phase 4
19 Autonomic Agents Phase 4
20 Bronchodilator Agents Phase 4
21
Fluticasone Phase 4 80474-14-2, 90566-53-3 22833648 62924
22 Respiratory System Agents Phase 4
23 Amotosalen Phase 4,Phase 2
24 Ficusin Phase 4,Phase 2
25 Furocoumarins Phase 4,Phase 2
26 glucocorticoids Phase 4,Phase 2,Phase 3
27 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
28 Hormones Phase 4,Phase 2,Phase 3,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
30 Protective Agents Phase 4,Phase 3
31 abobotulinumtoxinA Phase 4
32 Botulinum Toxins Phase 4
33 Botulinum Toxins, Type A Phase 4
34 Cholinergic Agents Phase 4
35 Neuromuscular Agents Phase 4
36 Neurotransmitter Agents Phase 4
37 onabotulinumtoxinA Phase 4
38 Pharmaceutical Solutions Phase 4,Phase 2
39 Antioxidants Phase 4
40 Keratolytic Agents Phase 4
41 Radiation-Protective Agents Phase 4
42 Hylan Phase 4
43
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741 24759
44
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
45
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
46 Adjuvants, Immunologic Phase 3
47 Viscosupplements Phase 3
48 triamcinolone acetonide Phase 2, Phase 3
49 Triamcinolone diacetate Phase 2, Phase 3
50 Triamcinolone hexacetonide Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 104)

# Name Status NCT ID Phase Drugs
1 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
2 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
3 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
4 Punchgrafting Techniques for Vitiligo Unknown status NCT01377077 Phase 4
5 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients Unknown status NCT01640678 Phase 4
6 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4 Botulinum toxin A
7 NB-UVB and PUVA Vitiligo Study Completed NCT01732965 Phase 4
8 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients Completed NCT02458417 Phase 4
9 Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Completed NCT00469183 Phase 4 Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
10 A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique. Completed NCT00293163 Phase 4
11 Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI Completed NCT00891774 Phase 4
12 Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Recruiting NCT03199664 Phase 4
13 Topical Bimatoprost Solution 0.03%in Stable Vitiligo Withdrawn NCT01202513 Phase 4 Bimatoprost 0.03% topical ophthalmic solution
14 Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC Unknown status NCT02466997 Phase 3 tacrolimus;Placebo
15 Virus Early Transcription Factor (VETF) Multicenter Phototherapy Protocol Unknown status NCT00525395 Phase 3
16 A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Unknown status NCT02156427 Phase 3
17 Vitiligo Skin Transplantation Completed NCT00830713 Phase 3
18 Epidermal Cell Transplantation in Vitiligo Skin Completed NCT01629979 Phase 2, Phase 3
19 Excimer Lamp Versus Excimer Laser in Vitiligo Treatment Completed NCT00696358 Phase 3
20 Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo Completed NCT00807690 Phase 3 Tacrolimus ointment
21 Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Completed NCT00631865 Phase 3
22 Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo Completed NCT01087216 Phase 2, Phase 3 Bras B : The group control
23 Emervel Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds Completed NCT01205061 Phase 3
24 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) Recruiting NCT02608450 Phase 3 CB-03-01 cream, 1%;Vehicle cream
25 Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Terminated NCT02191748 Phase 2, Phase 3 Triamcinolone
26 Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control Terminated NCT01841008 Phase 2, Phase 3 Protopic;Placebo : Diprobase
27 Efficacy and Safety of ACH24 in the Treatment of Vitiligo Withdrawn NCT01419964 Phase 3 Group 01;Group 02
28 Comparative Study of Techniques in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo Withdrawn NCT01822379 Phase 2, Phase 3
29 Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo Unknown status NCT01766609 Phase 2 Triamcinolone Acetonide
30 Efficacy of Red Light in Vitiligo Unknown status NCT01787708 Phase 2
31 UVA 1 Phototherapy for Vitiligo Unknown status NCT01787695 Phase 2
32 Treatment and Complication of Bath PUVA in Vitiligo Unknown status NCT00380471 Phase 2
33 Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand Unknown status NCT01792245 Phase 2
34 Topical Ruxolitinib for the Treatment of Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
35 Melanocyte Transplantation for Patients With Stable Vitiligo. Completed NCT01701648 Phase 1, Phase 2
36 Atorvastatin in Active Vitiligo Completed NCT02432534 Phase 2 Atorvastatin
37 Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Completed NCT01382589 Phase 2 Afamelanotide
38 Clinical Trial of Simvastatin to Treat Generalized Vitiligo Completed NCT01517893 Phase 2 Simvastatin;Placebo
39 Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo Completed NCT01511965 Phase 1, Phase 2
40 Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo Completed NCT00134368 Phase 2 Etanercept
41 Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris Completed NCT00372307 Phase 2 Application of pimecrolimus
42 Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients Completed NCT00928902 Phase 2 low-dose IL-2
43 Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Recruiting NCT03123016 Phase 2 Apremilast
44 A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Recruiting NCT03099304 Phase 2 INCB018424 cream;Vehicle cream
45 Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo Recruiting NCT03358082 Phase 1, Phase 2 Tacrolimus 0.03% Ointment;Hydrocortisone Acetate 1% Ointment
46 The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo Recruiting NCT03247400 Phase 1, Phase 2 1% simvastatin-acid sodium salt ointment;1% atorvastatin calcium salt ointment
47 Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO Active, not recruiting NCT03036995 Phase 2 Apremilast
48 Efficacy of Autologous Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo Terminated NCT01923142 Phase 2
49 A New Micrografting Technique for Vitiligo Terminated NCT01262547 Phase 2
50 Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo Model Unknown status NCT00172939 Phase 1

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:
JACE
Embryonic/Adult Cultured Cells Related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:
Cultured epidermis (JACE PMIDs: 23265935 17465819 11987545

Cochrane evidence based reviews: vitiligo

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Genetic tests related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

# Genetic test Affiliating Genes
1 Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 28 NLRP1
2 Vitiligo 28

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

38
Skin, Eye, Thyroid, Retina, Bone

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

(show top 50) (show all 1013)
# Title Authors Year
1
Generalized eruptive keratoacanthoma with vitiligo followed by the development of prurigo nodularis: A case report and published work review. ( 29058335 )
2018
2
Relationship between Disease Activity and<i>Helicobacter pylori</i>Infection in Patients with Vitiligo. ( 29441304 )
2018
3
Vitiligo: Not Simply a Skin Disease. ( 28528606 )
2017
4
Oxidative stress drives CD8(+) T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes. ( 27826097 )
2017
5
Reduced immunohistochemical expression of adhesion molecules in vitiligo skin biopsies. ( 28214208 )
2017
6
Autoimmune encephalitis associated with vitiligo? ( 28778439 )
2017
7
Post-Finasteride Adverse Effects in Male Androgenic Alopecia: A Case Report of Vitiligo. ( 28222425 )
2017
8
Metabo-miR: miR-211 Regulates Mitochondrial Energy Metabolism in Vitiligo. ( 28843294 )
2017
9
Unwanted lentigines after topical tacrolimus for vitiligo. ( 28762481 )
2017
10
Successful Repigmentation of Vitiligo-Like Hypopigmentation in a Case of Acanthosis Nigricans. ( 28392666 )
2017
11
Genetic variants of interferon-gamma and its mRNA expression and inflammatory parameters in the pathogenesis of vitiligo. ( 28273427 )
2017
12
Onychomatricoma in a Patient With Extensive Vitiligo. ( 28719440 )
2017
13
Increased systemic and epidermal levels of IL-17A and IL-1I^ promotes progression of non-segmental vitiligo. ( 28082234 )
2017
14
Autologous cell suspension grafting in segmental vitiligo and piebaldism: a randomised controlled trial comparing full-surface and fractional CO2 laser recipient site preparations. ( 28403523 )
2017
15
Differences in the melanosome distribution within the epidermal melanin units and its association with the impairing background of leukoderma in vitiligo and halo nevi: a retrospective study. ( 28314912 )
2017
16
Association of protein tyrosine phosphatase, non-receptor type 22 +1858Ca89T polymorphism and susceptibility to vitiligo: Systematic review and meta-analysis. ( 28164884 )
2017
17
A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat. ( 28700671 )
2017
18
S100B Is a Potential Disease Activity Marker in Nonsegmental Vitiligo. ( 28212812 )
2017
19
Coexistence of eruptive syringoma and bilateral nipple vitiligo: Could there be a common immunopathogenesis? ( 28971181 )
2017
20
The Use of Adipose-Derived Stem Cells in Selected Skin Diseases (Vitiligo, Alopecia, and Nonhealing Wounds). ( 28904532 )
2017
21
Oxidative stress-induced overexpression of miR-25: the mechanism underlying the degeneration of melanocytes in vitiligo. ( 26315342 )
2016
22
Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy. ( 27516894 )
2016
23
Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. ( 26787886 )
2016
24
Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. ( 26801009 )
2016
25
Successful Treatment of Vitiligo Associated with Vogt-Koyanagi-Harada Disease. ( 27981622 )
2016
26
Genetic polymorphism of the Nrf2 promoter region is associated with vitiligo risk in Han Chinese populations. ( 27222475 )
2016
27
Understanding autoimmunity of vitiligo and alopecia areata. ( 27191524 )
2016
28
Association of class I and II HLA alleles and haplotypes with susceptibility to vitiligo: a study of patients with vitiligo from southeast Brazil. ( 26769539 )
2016
29
Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay. ( 27110718 )
2016
30
Optimising size and depth of punch grafts in autologous transplantation of vitiligo and piebaldism: a randomised controlled trial. ( 27309418 )
2016
31
IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo. ( 27388717 )
2016
32
Autoimmune vitiligo in rheumatic disease in the mestizo Mexican population. ( 27446537 )
2016
33
Vitiligo in association with vernal keratoconjunctivitis. ( 27330391 )
2016
34
Glutathione Peroxidase Level in Patients with Vitiligo: A Meta-Analysis. ( 27218102 )
2016
35
Discoidin domain receptor-1 as a player in impairment of melanocytes adhesion process in vitiligo. ( 26091274 )
2016
36
Analysis of Manganese Superoxide Dismutase and Glutathione Peroxidase 1 Gene Polymorphisms in Vitiligo. ( 27100222 )
2016
37
Association analysis of class II cytokine and receptor genes in vitiligo patients. ( 26429320 )
2016
38
Association study between melanocortin-1 receptor gene polymorphisms and occurrence of vitiligo in a Taiwanese population: possible explanation for lack of increased UV-related damage in vitiligo skin. ( 26670452 )
2016
39
Lichen Nitidus Arising on Vitiligo: A New Variant of the Isotopic Coresponse. ( 27372544 )
2016
40
Clinical Significance of Serum Soluble CD Molecules to Assess Disease Activity in Vitiligo. ( 27556155 )
2016
41
Alopecia, halo nevi and vitiligo in a pediatric case of Turner's syndrome. ( 27238352 )
2016
42
HLA-DQB1 gene polymorphisms and non-segmental vitiligo: A case-control study in the Korean population. ( 26817698 )
2016
43
Study of the comparative expression of CXCL9, CXCL10 and IFNI^ in vitiligo and alopecia areata patients. ( 27863059 )
2016
44
Neurofibromatosis Type 1 and Vitiligo, a Rare Association. ( 28031143 )
2016
45
Concomitant appearance of morphea and vitiligo in a patient with autoimmune thyroiditis. ( 27605907 )
2016
46
Evaluation of serum trail level and DR4 gene variants as biomarkers for vitiligo patients. ( 26404509 )
2016
47
Alopecia areata, thyroiditis and vitiligo vulgaris in a Japanese patient with smoldering type adult T-cell leukemia/lymphoma. ( 27651025 )
2016
48
Oxidative Stress and Immune System in Vitiligo and Thyroid Diseases. ( 25838868 )
2015
49
A novel FoxD3 Variant Is Associated With Vitiligo and Elevated Thyroid Auto-Antibodies. ( 26267147 )
2015
50
The association between tumor necrosis factor-I+-308 G/A polymorphism and risk for vitiligo: a meta-analysis. ( 26224639 )
2015

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

71
# Symbol AA change Variation ID SNP ID
1 NLRP1 p.Leu155His VAR_033239 rs12150220

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 NLRP1 NM_001033053.2(NLRP1): c.464T> A (p.Leu155His) single nucleotide variant risk factor rs12150220 GRCh37 Chromosome 17, 5485367: 5485367

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1.

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Pathways related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to KEGG:

36
# Name Kegg Source Accession
1 NOD-like receptor signaling pathway hsa04621

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

Cellular components related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome GO:0042470 9.13 PMEL TYR TYRP1
2 melanosome membrane GO:0033162 8.62 TYR TYRP1

Biological processes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome organization GO:0032438 9.43 PMEL TYRP1
2 hydrogen peroxide catabolic process GO:0042744 9.4 CAT TPO
3 melanocyte differentiation GO:0030318 9.37 MITF TYRP1
4 embryonic hemopoiesis GO:0035162 9.32 KITLG TPO
5 dopamine biosynthetic process GO:0042416 9.26 DDC GCH1
6 tetrahydrobiopterin biosynthetic process GO:0006729 9.16 GCH1 PCBD1
7 pigmentation GO:0043473 9.13 MITF TYR TYRP1
8 melanin biosynthetic process GO:0042438 8.8 PMEL TYR TYRP1

Molecular functions related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peroxidase activity GO:0004601 8.62 CAT TPO

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....